Dr. Daud on Challenges Facing the Treatment Landscape for Melanoma

Adil Daud, MD
Published: Thursday, Oct 19, 2017



Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

One question that remains is which treatment patients should receive. According to Daud, there are advantages and disadvantages to each treatment option.

For most treatments, there will be at most 20% complete responses, but more research is needed to be done to increase that percentage. Potentially combining therapies could increase the response rates for patients, states Daud.

<<< View more from the World Congress of Melanoma


Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

One question that remains is which treatment patients should receive. According to Daud, there are advantages and disadvantages to each treatment option.

For most treatments, there will be at most 20% complete responses, but more research is needed to be done to increase that percentage. Potentially combining therapies could increase the response rates for patients, states Daud.

<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x